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Study objectives: Two patients diagnosed with interstitial lung disease (ILD)
secondary to pulmonary neuroendocrine cell (PNEC) hyperplasia are presented.
Background: Pulmonary neuroendocrine cell hyperplasia (PNECH) is a rare entity
worldwide and few cases presenting as ILD have been reported. Following the
consensus criteria established by the American Thoracic Society (ATS) and the
European Respiratory Society (ERS), three patients from among 500 ILD patients over
the last 10 years in our institution were diagnosed with PNECH. The diagnosis was
established by open lung biopsy using specific stains to demonstrate neuroendocrine
cells in lung tissue.
Methods: Patients were questioned on their medical and pathological history,
occupational or environmental exposure to toxic substances and any relationship
with smoking. In addition, were recorded symptoms at presentation, physical signs,
analytic and respiratory function results, chest X-ray and CT scan features,
bronchoscopy findings including bronchoalveolar lavage and transbronchial biopsy,
and open lung biopsy findings.
Results: In these two patients, PNECH was the only cause of their diffuse lung
disease. Clinical signs and symptoms (cough, expectoration and progressive dyspnea)
were similar to other idiopathic interstitial pneumonias and radiologic features
(ground-glass infiltrates in mosaic pattern) were consistent with those of non-
specific interstitial pneumonia or the onset of hypersensitivity pneumonitis.Elsevier Ltd. All rights reserved.
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Transbronchial and open biopsy findings are described, as well as the treatment
and course of the disease. The two patients had a favorable outcome.
Conclusions: Two cases of ILD secondary to PNEC hyperplasia are presented, with
clinical and radiological findings that might be mistaken for other types of idiopathic
interstitial pneumonias. The disease course is described and the possible
etiopathogenic role that PNECs might play in the development of lung fibrosis is
discussed.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Pulmonary neuroendocrine cells (PNEC) are epithe-
lial cells distributed along the bronchial mucosa.1,2
Their main activity is paracrine in nature3 and it is
more pronounced during the fetal and neonatal
period, when they play a major role in pulmonary
development.1–3 Pulmonary neuroendocrine cell
hyperplasia (PNECH) was first described in persons
living at high altitudes as a probable regenerative
or adaptive response to hypoxia.4–6 It has also been
associated with several lung processes, such as
bronchiectasis,5 emphysema,5 cystic fibrosis,7 tu-
berculosis,8 abscesses,8 other chronic inflammatory
lung diseases,5–8 and pulmonary fibrosis.9
Few reported cases of PNECH have manifested
clinically as diffuse interstitial lung disease
(ILD).9–12 Synthesis of various substances by the
hyperplastic neuroendocrine cells, such as bombe-
sin, which exert chemotactic and mitogenic effects
on fibroblasts and smooth muscle cells, could lead
to inflammation and subsequent fibrosis of the
airways.9,13Material and methods
Patients
Among the 500 patients with diffuse ILD consecu-
tively studied in our hospital outpatient clinic in
last 10 years, 140 (28%) of them being submitted to
open lung biopsy, only two patients were diagnosed
with PNECH.Diagnostic protocol
The consensus criteria about pulmonary fibrosis of
the American Thoracic Society (ATS) and European
Respiratory Society (ERS) were followed for diag-
nosis and treatment.14,15Case studies (Table 1)
Case 1: A 67-year-old woman, who born and lived
for 37 years at 497m above sea level. She had a
chronic cough and slight (occasionally greenish)
expectoration. At physical examination ‘‘velcro’’
crackles were audible. The chest-X-ray showed a
bilateral interstitial pattern. High-resolution com-
puter tomography (HRCT) of thorax disclosed areas
of ground glass in a mosaic distribution. Function
testing was consistent with a restrictive ventilatory
pattern (Table 1). Bronchoalveolar lavage (BAL)
was normal (macrophages 89%, lymphocytes 9%,
and polymorphonuclear cells 2%). Transbronchial
and bronchial biopsies were inconclusive. Open
lung biopsy showed structurally preserved lung
parenchyma with fibrosis and slight bronchiolar
lymphohistiocytic inflammation with neuroendo-
crine cell hyperplasia. Chromogranin stain was
positive for neuroendocrine cells and demonstrated
the presence of a tumorlet. The patient was started
on long-term inhaled b2 agonists plus corticoster-
oids, with frank improvement of clinical symptoms
and respiratory function parameters, which has
persisted over the last 2 years.
Case 2: A 40-year-old woman, living in a city
located more than 2000m above sea level. Three
years before referral to our institution, the patient
developed progressive dyspnea and a dry cough. At
physical examination only wheezing was audible.
Chest X-ray showed a diffuse interstitial pattern and
HRCTof thorax demonstrated ground glass infiltrates,
septal thickening and fibrotic honeycombing. Open
lung biopsy was decided and PNEC hyperplasia was
diagnosed. The patient was started on oral and
inhaled corticosteroids, long-term b2 agonists and
anticholinergic agents, with functional improvement.
Only dyspnea of grade I persisted up to 5 years later.Discussion
PNCH is a rare entity worldwide and few cases
presenting as diffuse ILD have been reported in two
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Table 1 Clinical, analytic, functional, and radiologic characteristics, and diagnosis, treatment and follow up of
three patients with PNEC hyperplasia.
Case 1 Case 2
Age/sex 67/W 40/W
Occupation Housewife Worker in waste water treatment
plant
High altitude 497m 42000m
Smoker No No
Prior medication Nifedipine, diosmin, diazepam and
enalapril
No
Contact with toxic substances Chronic contact of hydrochloric
acid and bleach.
Diverse substances in a waste water
treatment plant.
Symptoms Cough with slight expectoration
and progressive dyspnea
Progressive dyspnea and
progressive dry cough
Physical signs Crepitant rales, bronchospam and
slight fever
Wheezing
Initial lung function FVC 1.02 (42%) FVC 1.85 (55%)
FEV1 1.02 (49.5%) FEV1 1.48 (56%)
FVC % FEV1 84% FVC % FEV1 80%
TLC 3.39 (84%) TLC 3.29 (85%)
RV 1.85 (95%) RV 1.29 (86%)
Final lung function FVC 2.37 (58%) FVC 3.00 (87%)
FEV1 1.93 (61%) FEV1 2.70 (95%)
FVC % FEV1 95%
TLC 2.98 (74%)
RV 1.56 (80%)
Chest X-ray Diffuse interstitial pattern Diffuse interstitial pattern
Chest HRCT Ground glass infiltrates, with area
of mosaic pattern in geographic
distribution and bronchiectasis
Ground glass infiltrates,
bronchiectasis and mediastinal
lymphadenopathy
Transbronchial biopsy Lymphoplasmocytic bronchitis,
intra-alveolar foam cells
Mild mixed bronchitis
Open lung biopsy Neuroendocrine cell hyperplasia
and tumorlet
Neuroendocrine cell hyperplasia
Treatment Oral corticosteroids, inhaled
corticosteroids, b adrenergic
agents
Oral corticosteroids, inhaled
corticosteroids, b adrenergic
agents
Follow up Occasional episodes of cough and
bronchospasm stable after 2 years
Considerable improvement Stable
for 5 years
Complications Diffuse esophageal spasm Cushingoid syndrome
L.J. Reyes et al.1842series of patients (Pub-Med 1975–2004).9,13 It is
also noteworthy that in the largest series of diffuse
ILD patients in recent years, published in the USA
and Europe (15–20), none of the patients included
has had a diagnosis of PNEC hyperplasia. Among the
200 causes of diffuse ILD for which assessment and
treatment have been standardized by the ATS/ERS,
PNEC hyperplasia is categorized within the group of
rare diffuse ILD (21–22).
The symptoms at presentation in the two pub-
lished series and in the present study consist of
progressive dyspnea and dry cough. Bilateral crepi-
tant rales in the lung bases on inspiration weredetected in only 25% of patients and there was no
clubbing or cyanosis. In our patients ‘‘velcro’’
crackles were detected in one patient, and wheezing
in another. The most common radiologic findings in
the published cases were reticulonodular infil-
trates,9,13 whereas in the present series a combina-
tion of reticular and alveolar infiltrates was found.
The described chest HRCT features include in those
series diffuse ground glass infiltrates, specifically in a
mosaic pattern, and airway wall thickening with
occasional micronodules, findings that are also found
of nonspecific interstitial pneumonia (21) and hyper-
sensitivity pneumonitis (22); these features were
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provide relevant data with regard to BAL findings.
Patients in the present study were treated with oral
and inhaled corticosteroids; inhaled b-adrenergic
agents were added when there was associated
clinical hyperreactivity. The response was good in
two patients.References
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